Peroxisome proliferator-activated receptor-γ agonist rosiglitazone reverses the adverse effects of diet-induced obesity on oocyte quality

Endocrinology

Volumn 149, Issue 5, 2008, Pages 2646-2656

  Minge, Cadence E ^a   Bennett, Brenton D ^a   Norman, Robert J ^a   Robker, Rebecca L ^a,b  

^a UNIVERSITY OF ADELAIDE   (Australia)

^b UNIVERSITY OF ADELAIDE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

5 AMINO 4 IMIDAZOLECARBOXAMIDE RIBOSIDE; ADENYLATE KINASE; CD36 ANTIGEN; GLUCOSE; I KAPPA B KINASE INHIBITOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; ROSIGLITAZONE; SALICYLATE SODIUM;

ANIMAL CELL; ARTICLE; BLASTOCYST; BLASTOMERE; CELL DIFFERENTIATION; CELL SURVIVAL; CHOLESTEROL TRANSPORT; CONTROLLED STUDY; EMBRYO DEVELOPMENT; FABP4 GENE; FEMALE; GENE; GLUCOSE METABOLISM; INSULIN RESISTANCE; MALE; MOUSE; NONHUMAN; OBESITY; OOCYTE; OVARY FUNCTION; OVULATION; PRIORITY JOURNAL; SEARB1 GENE;

ANIMALS; BLASTOMERES; CELL DIFFERENTIATION; CELLS, CULTURED; CYTOPROTECTION; DIET; DIET, ATHEROGENIC; EMBRYO CULTURE TECHNIQUES; EMBRYO, MAMMALIAN; EMBRYONIC DEVELOPMENT; FEMALE; GENE EXPRESSION REGULATION; HYPOGLYCEMIC AGENTS; MICE; MICE, INBRED C57BL; OBESITY; OOCYTES; OVARY; OVULATION; PPAR GAMMA; THIAZOLIDINEDIONES;

EID: 42449132961     PISSN: 00137227     EISSN: 00137227     Source Type: Journal    
DOI: 10.1210/en.2007-1570     Document Type: Article

References (79)

1. Zaadstra BM, Seidell JC, Van Noord PA, te Velde ER, Habbema JD, Vrieswijk B, Karbaat J 1993 Fat and female fecundity: prospective study of effect of body fat distribution on conception rates. BMJ 306:484-487
2. Pasquali R, Pelusi C, Genghini S, Cacciari M, Gambineri A 2003 Obesity and reproductive disorders in women. Hum Reprod Update 9:359-372
3. Ku SY, Kim SD, Jee BC, Suh CS, Choi YM, Kim JG, Moon SY, Kim SH 2006 Clinical efficacy of body mass index as predictor of in vitro fertilization and embryo transfer outcomes. J Korean Med Sci 21:300-303
4. Gesink Law DC, Maclehose RF, Longnecker MP 2007 Obesity and time to pregnancy. Hum Reprod 22:414-420
5. Sherman BM, Korenman SG 1974 Measurement of serum LH, FSH, estradiol and progesterone in disorders of the human menstrual cycle: the inadequate luteal phase. J Clin Endocrinol Metab 39:145-149
6. Lashen H, Ledger W, Bernal AL, Barlow D 1999 Extremes of body mass do not adversely affect the outcome of superovulation and in-vitro fertilization. Hum Reprod 14:712-715
7. Salha O, Dada T, Sharma V 2001 Influence of body mass index and self-administration of hCG on the outcome of IVF cycles: a prospective cohort study. Hum Fertil (Camb) 4:37-42
8. Fedorcsak P, Dale PO, Storeng R, Ertzeid G, Bjercke S, Oldereid N, Omland AK, Abyholm T, Tanbo T 2004 Impact of overweight and underweight on assisted reproduction treatment. Hum Reprod 19:2523-2528
9. Tian L, Shen H, Lu Q, Norman RJ, Wang J 2007 Insulin resistance increases the risk of spontaneous abortion after assisted reproduction technology treatment. J Clin Endocrinol Metab 92:1430-1433
10. Norman RJ, Chura LR, Robker RL 2 June 2007 Effects of obesity on assisted reproductive technology outcomes. Fertil Steril [Epub ahead of print]
11. Nelson SM, Fleming RF 2007 The preconceptual contraception paradigm: obesity and infertility. Hum Reprod 22:912-915
12. Harborne L, Fleming R, Lyall H, Norman J, Sattar N 2003 Descriptive review of the evidence for the use of metformin in polycystic ovary syndrome. Lancet 361:1894-1901
13. Poretsky L, Kalin MF 1987 The gonadotropic function of insulin. Endocr Rev 8:132-141
14. Poretsky L, Clemons J, Bogovich K 1992 Hyperinsulinemia and human chorionic gonadotropin synergistically promote the growth of ovarian follicular cysts in rats. Metabolism 41:903-910
15. Kuscu NK, Koyuncu F, Ozbilgin K, Inan S, Tuglu I, Karaer O 2002 Insulin: does it induce follicular arrest in the rat ovary? Gynecol Endocrinol 16:361-364
16. Poretsky L, Cataldo NA, Rosenwaks Z, Giudice LC 1999 The insulin-related ovarian regulatory system in health and disease. Endocr Rev 20:535-582
17. Corton JM, Gillespie JG, Hawley SA, Hardie DG 1995 5-Aminoimidazole-4-carboxamide ribonucleoside. A specific method for activating AMP-activated protein kinase in intact cells? Eur J Biochem 229:558-565
18. Musi N, Hirshman MF, Nygren J, Svanfeldt M, Bavenholm P, Rooyackers O, Zhou G, Williamson JM, Ljunqvist O, Efendic S, Moller DE, Thorell A, Goodyear LJ 2002 Metformin increases AMP-activated protein kinase activity in skeletal muscle of subjects with type 2 diabetes. Diabetes 51:2074-2081
19. Musi N, Goodyear LJ 2002 Targeting the AMP-activated protein kinase for the treatment of type 2 diabetes. Curr Drug Targets Immune Endocr Metabol Disord 2:119-127
20. Carling D, Hardie DG 1989 The substrate and sequence specificity of the AMP-activated protein kinase. Phosphorylation of glycogen synthase and phosphorylase kinase. Biochim Biophys Acta 1012:81-86
21. Davies SP, Sim AT, Hardie DG 1990 Location and function of three sites phosphorylated on rat acetyl-CoA carboxylase by the AMP-activated protein kinase. Eur J Biochem 187:183-190
22. Davies SP, Carling D, Munday MR, Hardie DG 1992 Diurnal rhythm of phosphorylation of rat liver acetyl-CoA carboxylase by the AMP-activated protein kinase, demonstrated using freeze-clamping. Effects of high fat diets. Eur J Biochem 203:615-623
23. Clarke PR, Hardie DG 1990 Regulation of HMG-CoA reductase: identification of the site phosphorylated by the AMP-activated protein kinase in vitro and in intact rat liver. EMBO J 9:2439-2446
24. Jessen N, Pold R, Buhl ES, Jensen LS, Schmitz O, Lund S 2003 Effects of AICAR and exercise on insulin-stimulated glucose uptake, signaling, and GLUT-4 content in rat muscles. J Appl Physiol 94:1373-1379
25. Merrill GF, Kurth EJ, Hardie DG, Winder WW 1997 AICA riboside increases AMP-activated protein kinase, fatty acid oxidation, and glucose uptake in rat muscle. Am J Physiol 273(6 Pt 1):E1107-E1112
26. Russell 3rd RR, Bergeron R, Shulman GI, Young LH 1999 Translocation of myocardial GLUT-4 and increased glucose uptake through activation of AMPK by AICAR. Am J Physiol 277(2 Pt 2):H643-H649
27. Kurth-Kraczek EJ, Hirshman MF, Goodyear LJ, Winder WW 1999 5′ AMP-activated protein kinase activation causes GLUT4 translocation in skeletal muscle. Diabetes 48:1667-1671
28. Patrignani P, Panara MR, Sciulli MG, Santini G, Renda G, Patrono C 1997 Differential inhibition of human prostaglandin endoperoxide synthase-1 and -2 by nonsteroidal anti-inflammatory drugs. J Physiol Pharmacol 48:623-631
29. Giuliano F, Warner TD 1999 Ex vivo assay to determine the cyclooxygenase selectivity of non-steroidal anti-inflammatory drugs. Br J Pharmacol 126:1824-1830
30. Warner TD, Giuliano F, Vojnovic I, Bukasa A, Mitchell JA, Vane JR 1999 Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: a full in vitro analysis. Proc Natl Acad Sci USA 96:7563-7568
31. Mitchell JA, Saunders M, Barnes PJ, Newton R, Belvisi MG 1997 Sodium salicylate inhibits cyclo-oxygenase-2 activity independently of transcription factor (nuclear factor κB) activation: role of arachidonic acid. Mol Pharmacol 51:907-912
32. Kopp E, Ghosh S 1994 Inhibition of NF-κB by sodium salicylate and aspirin. Science 265:956-959
33. Yin MJ, Yamamoto Y, Gaynor RB 1998 The anti-inflammatory agents aspirin and salicylate inhibit the activity of I(κ)B kinase-β. Nature 396:77-80
34. Baron SH 1982 Salicylates as hypoglycemic agents. Diabetes Care 5:64-71
35. Shoelson SE, Lee J, Yuan M 2003 Inflammation and the IKK β/I κ B/NF-κ B axis in obesity- and diet-induced insulin resistance. Int J Obes Relat Metab Disord 27(Suppl 3):S49-S52
36. Cai D, Yuan M, Frantz DF, Melendez PA, Hansen L, Lee J, Shoelson SE 2005 Local and systemic insulin resistance resulting from hepatic activation of IKK-β and NF-κB. Nat Med 11:183-190
37. Mudaliar S, Henry RR 2001 New oral therapies for type 2 diabetes mellitus: the glitazones or insulin sensitizers. Annu Rev Med 52:239-257
38. Lehmann JM, Moore LB, Smith-Oliver TA, Wilkison WO, Willson TM, Kliewer SA 1995 An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR γ). J Biol Chem 270:12953-12956
39. Minge CE, Robker RL, Norman J, PPAR γ: coordinating metabolic and immune contributions to female fertility. PPAR Res, in press
40. Schoonjans K, Martin G, Staels B, Auwerx J 1997 Peroxisome proliferator-activated receptors, orphans with ligands and functions. Curr Opin Lipidol 8:159-166
41. Lemay DG, Hwang DH 2006 Genome-wide identification of peroxisome proliferator response elements using integrated computational genomics. J Lipid Res 47:1583-1587
42. Semple RK, Chatterjee VK, O'Rahilly S 2006 PPAR γ and human metabolic disease. J Clin Invest 116:581-589
43. Hamm JK, el Jack AK, Pilch PF, Farmer SR 1999 Role of PPAR γ in regulating adipocyte differentiation and insulin-responsive glucose uptake. Ann NY Acad Sci 892:134-145
44. Wilson-Fritch L, Nicoloro S, Chouinard M, Lazar MA, Chui PC, Leszyk J, Straubhaar J, Czech MP, Corvera S 2004 Mitochondrial remodeling in adipose tissue associated with obesity and treatment with rosiglitazone. J Clin Invest 114:1281-1289
45. Carmona MC, Louche K, Nibbelink M, Prunet B, Bross A, Desbazeille M, Dacquet C, Renard P, Casteilla L, Penicaud L 2005 Fenofibrate prevents Rosiglitazone-induced body weight gain in ob/ob mice. Int J Obes (Lond) 29:864-871
46. Gepdiremen A, Suleyman H 2003 Intraperitoneal administration of salicylate dose-dependently prevents stress-induced ulcer formation in rats. Pol J Pharmacol 55:209-212
47. Cuzzocrea S, Pisano B, Dugo L, Ianaro A, Maffia P, Patel NS, Di Paola R, Ialenti A, Genovese T, Chatterjee PK, Di Rosa M, Caputi AP, Thiemermann C 2004 Rosiglitazone, a ligand of the peroxisome proliferator-activated receptor-γ, reduces acute inflammation. Eur J Pharmacol 483:79-93
48. Gardner DK 1994 Mammalian embryo culture in the absence of serum or somatic cell support. Cell Biol Int 18:1163-1179
49. Gardner DK, Lane M, Watson AJ 2004 A laboratory guide to the mammalian embryo. New York: Oxford University Press
50. Barnes FL, Crombie A, Gardner DK, Kausche A, Lacham-Kaplan O, Suikkari AM, Tiglias J, Wood C, Trounson AO 1995 Blastocyst development and birth after in-vitro maturation of human primary oocytes, intracytoplasmic sperm injection and assisted hatching. Hum Reprod 10:3243-3247
51. Hardy K, Handyside AH, Winston RM 1989 The human blastocyst: cell number, death and allocation during late preimplantation development in vitro. Development 107:597-604
52. Srivastava RA 2003 Scavenger receptor class B type I expression in murine brain and regulation by estrogen and dietary cholesterol. J Neurol Sci 210:11-18
53. Lane M, Gardner DK 1997 Differential regulation of mouse embryo development and viability by amino acids. J Reprod Fertil 109:153-164
54. Kwong WY, Wild AE, Roberts P, Willis AC, Fleming TP 2000 Maternal undernutrition during the preimplantation period of rat development causes blastocyst abnormalities and programming of postnatal hypertension. Development 127:4195-4202
55. Garris DR, Garris BL 2003 Diabetes (db/db) mutation-induced ovarian involution: progressive hypercytolipidemia. Exp Biol Med (Maywood) 228:1040-1050
56. Garris DR, Williams SK, West L 1985 Morphometric evaluation of diabetes-associated ovarian atrophy in the C57BL/KsJ mouse: relationship to age and ovarian function. Anat Rec 211:434-443
57. Olatinwo MO, Bhat GK, Stah CD, Mann DR 2005 Impact of gonadotropin administration on folliculogenesis in prepubertal ob/ob mice. Mol Cell Endocrinol 245:121-127
58. Hamm ML, Bhat GK, Thompson WE, Mann DR 2004 Folliculogenesis is impaired and granulosa cell apoptosis is increased in leptin-deficient mice. Biol Reprod 71:66-72
59. Kakar MA, Maddocks S, Lorimer MF, Kleemann DO, Rudiger SR, Hartwich KM, Walker SK 2005 The effect of peri-conception nutrition on embryo quality in the superovulated ewe. Theriogenology 64:1090-1103
60. Picard F, Auwerx J 2002 PPAR(γ) and glucose homeostasis. Annu Rev Nutr 22:167-197
61. Ehrmann DA, Schneider DJ, Sobel BE, Cavaghan MK, Imperial J, Rosenfield RL, Polonsky KS 1997 Troglitazone improves defects in insulin action, insulin secretion, ovarian steroidogenesis, and fibrinolysis in women with polycystic ovary syndrome. J Clin Endocrinol Metab 82:2108-2116
62. Gasic S, Bodenburg Y, Nagamani M, Green A, Urban RJ 1998 Troglitazone inhibits progesterone production in porcine granulosa cells. Endocrinology 139:4962-4966
63. Komar CM, Braissant O, Wahli W, Curry Jr TE 2001 Expression and localization of PPARs in the rat ovary during follicular development and the periovulatory period. Endocrinology [Erratum (2001) 142:5320] 142:4831-4838
64. Froment P, Fabre S, Dupont J, Pisselet C, Chesneau D, Staels B, Monget P 2003 Expression and functional role of peroxisome proliferator-activated receptor-γ in ovarian folliculogenesis in the sheep. Biol Reprod 69:1665-1674
65. Minge CE, Ryan NK, Van Der Hoek KH, Robker RL, Norman RJ 2006 Troglitazone regulates peroxisome proliferator-activated receptors and inducible nitric oxide synthase in murine ovarian macrophages. Biol Reprod 74:153-160
66. Mohan M, Malayer JR, Geisert RD, Morgan GL 2002 Expression patterns of retinoid X receptors, retinaldehyde dehydrogenase, and peroxisome proliferator activated receptor γ in bovine preattachment embryos. Biol Reprod 66:692-700
67. Komar CM, Curry Jr TE 2002 Localization and expression of messenger RNAs for the peroxisome proliferator-activated receptors in ovarian tissue from naturally cycling and pseudopregnant rats. Biol Reprod 66:1531-1539
68. Teboul L, Febbraio M, Gaillard D, Amri EZ, Silverstein R, Grimaldi PA 2001 Structural and functional characterization of the mouse fatty acid translocase promoter: activation during adipose differentiation. Biochem J 360(Pt 2):305-312
69. Malerod L, Sporstol M, Juvet LK, Mousavi A, Gjoen T, Berg T 2003 Hepatic scavenger receptor class B, type I is stimulated by peroxisome proliferator-activated receptor γ and hepatocyte nuclear factor 4α. Biochem Biophys Res Commun 305:557-565
70. Graves RA, Tontonoz P, Spiegelman BM 1992 Analysis of a tissue-specific enhancer: ARF6 regulates adipogenic gene expression. Mol Cell Biol 12:1202-1208
71. Tontonoz P, Nagy L, Alvarez JG, Thomazy VA, Evans RM 1998 PPARγ promotes monocyte/macrophage differentiation and uptake of oxidized LDL. Cell 93:241-252
72. Chinetti G, Gbaguidi FG, Griglio S, Mallat Z, Antonucci M, Poulain P, Chapman J, Fruchart JC, Tedgui A, Najib-Fruchart J, Staels B 2000 CLA-1/SR-BI is expressed in atherosclerotic lesion macrophages and regulated by activators of peroxisome proliferator-activated receptors. Circulation 101:2411-2417
73. Tontonoz P, Graves RA, Budavari AI, Erdjument-Bromage H, Lui M, Hu E, Tempst P, Spiegelman BM 1994 Adipocyte-specific transcription factor ARF6 is a heterodimeric complex of two nuclear hormone receptors, PPAR γ and RXR α. Nucleic Acids Res 22:5628-5634
74. Nourani MR, Owada Y, Kitanaka N, Sakagami H, Hoshi H, Iwasa H, Spener F, Kondo H 2005 Occurrence of immunoreactivity for adipocyte-type fatty acid binding protein in degenerating granulosa cells in atretic antral follicles of mouse ovary. J Mol Histol 36:491-497
75. Tan NS, Shaw NS, Vinckenbosch N, Liu P, Yasmin R, Desvergne B, Wahli W, Noy N 2002 Selective cooperation between fatty acid binding proteins and peroxisome proliferator-activated receptors in regulating transcription. Mol Cell Biol [Erratum (2002) 22:6318]22:5114-5127
76. Seto-Young D, Avtanski D, Strizhevsky M, Parikh G, Patel P, Kaplun J, Holcomb K, Rosenwaks Z, Poretsky L 2007 Interactions among peroxisome proliferator activated receptor-γ, insulin signaling pathways, and steroidogenic acute regulatory protein in human ovarian cells. J Clin Endocrinol Metab 92:2232-2239
77. Gasic S, Nagamani M, Green A, Urban RJ 2001 Troglitazone is a competitive inhibitor of 3β-hydroxysteroid dehydrogenase enzyme in the ovary. Am J Obstet Gynecol 184:575-579
78. Chan LY, Yeung JH, Lau TK 2005 Placental transfer of rosiglitazone in the first trimester of human pregnancy. Fertil Steril 83:955-958
79. Klinkner DB, Lim HJ, Strawn Jr EY, Oldham KT, Sander TL 2006 An in vivo murine model of rosiglitazone use in pregnancy. Fertil Steril 86(Suppl 4):1074-1079